A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Inclusion Criteria:

• Participant has provided informed consent before initiation of any study-specificactivities/procedures.

• Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.

• Histologically or cytologically documented ES-SCLC (American Joint Committee onCancer, 2017, Stage IV SCLC [T any, N any, M1 a/b/c]), or T3 to T4 due to multiplelung nodules that are too extensive or have tumor/nodal volume that is too large tobe encompassed in a tolerable radiation plan.

• Measurable disease as defined per RECIST 1.1.

• Suitable to receive carboplatin, etoposide and durvalumab regimen as first-linetreatment per investigator clinical assessment.

• Minimum life expectancy ≥ 12 weeks.

Exclusion Criteria:

• Participants can have no history of other malignancy in the last 2 years.

• Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.

• They will have no history of severe or life-threatening events to immune-mediatedtherapy.

• History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6months prior to first dose of study treatment.

• They will have no active autoimmune or inflammatory disorders.

• Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B/C)infection.

• Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.

• History of solid organ transplant.

• They will not have had a myocardial infarction and/or symptomatic congestive heartfailure (New York Heart Association > class II) within 6 months prior to first doseof study treatment.